Pfizer Completed Acquisition of FoldRx

Pfizer Completed Acquisition of FoldRx
Oct 6, 2010
12:08pm

NEW YORK, Oct. 6 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) today announced the completion of its acquisition of FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company.

FoldRx Pharmaceuticals, Inc. is now a wholly owned subsidiary of Pfizer Inc.  

(Logo:  http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

Pfizer Inc: Working together for a healthier worldTM

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at www.pfizer.com

More information is available at www.pfizer.com. 

Follow Pfizer on www.Twitter.com/pfizer_news.

SOURCE Pfizer Inc.

For further information: Media, Gwen Fisher, +1-484-865-5160, Investors: Jennifer Davis, +1-212-733-0717

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.